Hillsdale Investment Management’s Relmada Therapeutics RLMD Stock Holding History

Hillsdale Investment Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-53,600	Closed	-$373K	–	744
2026 Q1	$373K	Buy	+53,600	New	+$254K	0.01%	444

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Hillsdale Investment Management's RLMD Position: Q2 2026 in Review

Hillsdale Investment Management sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 53,600 shares — an estimated $373K sold.

Hillsdale Investment Management first reported a position in RLMD in Q1 2026 and held it in 1 quarter. The position peaked at $373K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Hillsdale Investment Management reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
Hillsdale Investment Management sold 53,600 Relmada Therapeutics shares in Q2 2026, an estimated $373K.
Hillsdale Investment Management first reported a position in Relmada Therapeutics in Q1 2026 and held it in 1 quarter.
Hillsdale Investment Management's Relmada Therapeutics position peaked at $373K in Q1 2026.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.